Squamous cell carcinoma transformation from adenocarcinoma as an acquired resistance after the EGFR TKI therapy in (EGFR-mutated) non-small cell lung cancer.
作者信息
Shinohara Shinji, Ichiki Yoshinobu, Fukuichi Yukiko, Honda Yohei, Kanayama Masatoshi, Taira Akihiro, Nabe Yusuke, Kuwata Taiji, Takenaka Masaru, Oka Soichi, Chikaishi Yasuhiro, Hirai Ayako, Imanishi Naoko, Kuroda Koji, Yoneda Kazue, Noguchi Hirotsugu, Tanaka Fumihiro
机构信息
Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Department of Pathology and Cell Biology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
出版信息
J Thorac Dis. 2018 Jul;10(7):E526-E531. doi: 10.21037/jtd.2018.06.83.
Abstract
摘要
相似文献
1
Squamous cell carcinoma transformation from adenocarcinoma as an acquired resistance after the EGFR TKI therapy in (EGFR-mutated) non-small cell lung cancer.
J Thorac Dis. 2018 Jul;10(7):E526-E531. doi: 10.21037/jtd.2018.06.83.
2
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Lung Cancer. 2017 Nov;113:14-17. doi: 10.1016/j.lungcan.2017.08.024. Epub 2017 Sep 1.
3
Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma.
Lung Cancer. 2019 Aug;134:7-15. doi: 10.1016/j.lungcan.2019.05.024. Epub 2019 May 24.
4
Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
Lung Cancer. 2017 Jan;103:24-26. doi: 10.1016/j.lungcan.2016.11.012. Epub 2016 Nov 17.
5
Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Lung Cancer. 2014 Jul;85(1):19-24. doi: 10.1016/j.lungcan.2014.03.016. Epub 2014 Mar 23.
6
Squamous Cell Carcinoma "Transformation" Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas.
J Thorac Oncol. 2016 Apr;11(4):e49-51. doi: 10.1016/j.jtho.2015.12.096. Epub 2015 Dec 30.
7
Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Lung Cancer. 2015 Sep;89(3):357-9. doi: 10.1016/j.lungcan.2015.06.021. Epub 2015 Jun 29.
8
An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
Intern Med. 2018 Dec 1;57(23):3429-3432. doi: 10.2169/internalmedicine.0999-18. Epub 2018 Aug 10.
9
Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.
Lung Cancer. 2013 Apr;80(1):1-4. doi: 10.1016/j.lungcan.2012.12.019. Epub 2013 Jan 10.
10
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
Lung Cancer. 2017 Feb;104:58-64. doi: 10.1016/j.lungcan.2016.12.002. Epub 2016 Dec 14.
引用本文的文献
1
A Rare Histologic Transformation from EGFR-Positive Lung Adenocarcinoma to EGFR-Negative Squamous Cell Carcinoma After EGFR-TKIs Resistance: A Case Report.
Onco Targets Ther. 2025 Jul 18;18:803-809. doi: 10.2147/OTT.S513879. eCollection 2025.
2
TFF3 drives Hippo dependent EGFR-TKI resistance in lung adenocarcinoma.
Oncogene. 2025 Mar;44(11):753-768. doi: 10.1038/s41388-024-03244-5. Epub 2024 Dec 10.
3
Histological transformation in lung adenocarcinoma: Insights of mechanisms and therapeutic windows.
J Transl Int Med. 2024 Nov 6;12(5):452-465. doi: 10.1515/jtim-2024-0019. eCollection 2024 Nov.
4
Clonal dynamics and Stereo-seq resolve origin and phenotypic plasticity of adenosquamous carcinoma.
NPJ Precis Oncol. 2023 Aug 26;7(1):80. doi: 10.1038/s41698-023-00430-8.
5
Tissue Rigidity Increased during Carcinogenesis of NTCU-Induced Lung Squamous Cell Carcinoma In Vivo.
Biomedicines. 2022 Sep 23;10(10):2382. doi: 10.3390/biomedicines10102382.
6
Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC.
Cancers (Basel). 2022 Aug 18;14(16):3983. doi: 10.3390/cancers14163983.
7
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.
Int J Mol Sci. 2022 Apr 9;23(8):4164. doi: 10.3390/ijms23084164.
8
Characterization of non-small cell lung cancer transforming to small cell lung cancer and its response to EGFR-TKI: a case report.
Ann Transl Med. 2022 Jan;10(2):115. doi: 10.21037/atm-21-6991.
9
Histologic Changes in Non-Small Cell Lung Cancer under Various Treatments: A Comparison of Histology and Mutation Status in Serial Samples.
Cancer Res Treat. 2022 Jul;54(3):737-743. doi: 10.4143/crt.2021.773. Epub 2021 Sep 24.
10
Case Report: EGFR-Positive Early-Stage Lung Adenocarcinoma Transforming to Squamous Cell Carcinoma After TKI Treatment.
Front Oncol. 2021 Jun 8;11:696881. doi: 10.3389/fonc.2021.696881. eCollection 2021.
本文引用的文献
1
Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
Lung Cancer. 2017 Jan;103:24-26. doi: 10.1016/j.lungcan.2016.11.012. Epub 2016 Nov 17.
2
Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors.
Transl Lung Cancer Res. 2016 Aug;5(4):401-12. doi: 10.21037/tlcr.2016.07.10.
3
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol. 2016 Oct 1;34(28):3375-82. doi: 10.1200/JCO.2016.66.7162. Epub 2016 Jun 27.
4
Squamous Cell Carcinoma "Transformation" Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas.
J Thorac Oncol. 2016 Apr;11(4):e49-51. doi: 10.1016/j.jtho.2015.12.096. Epub 2015 Dec 30.
5
Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition.
J Thorac Oncol. 2015 Sep;10(9):e86-e88. doi: 10.1097/JTO.0000000000000571.
6
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1.
7
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Sci Transl Med. 2011 Mar 23;3(75):75ra26. doi: 10.1126/scitranslmed.3002003.
8
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Clin Lung Cancer. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039.
Zotero 插件